Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Pfizer to announced new data at cancer conference

Pfizer to announced new data at cancer conference

10th September 2008

Pfizer has announced it is to present a range of key study results at the upcoming annual conference of the European Society for Medical Oncology to be held in Stockholm, Sweden, from September 12th-16th 2008.

Results will include those for its leading anticancer drug Sutent (sunitinib malate), in addition to those for its investigational compound CP-751,871.

Updated phase III trial data of Sutent in patients with metastatic renal cell carcinoma patients will be presented at the event, together with a number of analyses assessing the cost effectiveness of Sutent as a first-line therapy in this indication.

The firm will present updated results for CP-751,871 in patients with non-small cell lung cancer.

Garry Nicholson, senior vice-president and general manager of the oncology business unit at Pfizer, said: “Pfizer has made a major commitment to oncology and invests a significant portion of research and development funds in cancer research across four scientific platforms and 22 compounds.”

He added that the company is keen to share its results with the international oncology community.

Earlier this month, Bristol-Myers Squibb and Pfizer announced the publication of new data on investigational anticoagulant apixaban in acute coronary syndrome patients.

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.